INmune Bio Inc.

Healthcare · Biotechnology · United States

Last price 1.6 USD (Oct 29, 2026, 4:00 PM EDT) · Market cap 49.21M

Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports

INmune Bio Inc., a clinical-stage immunology company, focuses on developing drugs to reprogram the patients innate immune system to treat disease in the United States. It intends to develop and commercialize product candidates to treat hematologic malignancies, solid tumors, and chronic inflammation. The company’s development programs include INKmune, which is in Phase 1 for the treatment of patients with high-risk myelodysplastic syndrome; and INB03, which is in Phase II for the treatment of breast cancer. It provides XPro1595 for the treatmen...